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Evidence isobtained for the presence oflipocortin-like proteins inhuman tracheal g and cells in culture. Using polyclonal antibodies to lipocortin 
I, indirect immunofluorescence studies demonstrate that lipocortin I is mainly confined to the tracheal gland cell surface. From cell membranes, 
four Ca2+-dependent proteins (35, 40, 45 and 67 kDa) were identified as lipocortin related proteins by using immunoblotting and fluorography 
following [35S]methionine m tabolic labeling experiments. A strong immunoreactivity for the 35 kDa protein was observed. Inaddition, lipocortin- 
like proteins with apparent Mr33, 35, 37 and 67 kDa, respectively, were released inthe apical culture medium by tracheal gland cells cultured on 
microporous membrane of a double chamber culture system. 
Lipocortin; Human tracheal g and; Cell culture 
1. INTRODUCTION 
Lipocortins are a family of calcium and 
phospholopid binding proteins described initially as 
glucocorticoid-induced and secreted proteins inhibiting 
phospholipase A2 in vitro and in vivo [1-15], and thus 
preventing the release of inflammatory mediators, pro- 
staglandin E2 and leukotrienes. Human respiratory 
diseases including acute and chronic bronchitis, asthma 
and cystic fibrosis are associated with excessive airway 
mucus production, mainly originating from sub- 
mucosal gland secretory cells [6,7]. Mechanisms 
possibly responsible for chronic mucus hypersecretion 
involve the increase in total number of mucus- 
producing cells [6] and/or the secretory effects of a 
number of locally released mediators including 
arachidonic acid metabolites and prostaglandins [8,9] 
as well as mediators released from activated inflam- 
matory cells [10]. Organ cultures (explants) of human 
[8] and cat [11] trachea, as well as human tracheal 
epithelium-cell cultures [12-15] generate numerous 
metabolites of arachidonic acid, predominantly pro- 
staglandin E2 and 15-hydroxyeicosatetraenoic acid 
(15-HETE) which have powerful stimulatory effects on 
respiratory glycoconjugate secretion [8,9]. Glucocor- 
ticoids have been shown to inhibit secretion of mucus in 
asthmatic airways [16,17] and in in vitro experiments 
using human and cat airway explants [18,19]. Lundgren 
et al. [19] speculated that the inhibitory action of dex- 
amethasone on mucus glycoprotein secretion is mainly 
due to the inhibition of arachidonic acid product for- 
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mation through the induction of lipocortin synthesis. 
Nevertheless, using whole airway explant cultures, it is 
impossible to know the cell types or tissues (surface 
ciliated cells, goblet cells, submucosal gland cells, 
migratory cells, vessels) responding to glucocorticoid 
treatment. Recently, Shimura et al. [20] demonstrated a 
direct inhibitory action of glucocorticoid on both basal 
glycoconjugate s cretion and stimulated secretion from 
cultured cat airway submucosal gland cells. According 
to the authors, these inhibitions are due to a reduction 
in the release of glycoconjugates without significant 
alteration in synthesis. As there is evidence that a 
lipocortin-like protein (calpactin) binds to cytoskeleton 
(actin) and promotes contact between the secretory 
vesicles and the plasma membrane during the exocytosis 
process [21,22], we have investigated the possibility that 
human airway gland secretory cells in culture produce 
lipocortin-like proteins. 
2. MATERIALS AND METHODS 
2.1. Cell culture on permeable filters 
Isolation and culture of airway submucosal gland cells were realiz- 
ed from human tracheas obtained 6-12 h post-mortem by using a
method of enzymatic dissociation previously described by Tournier et 
al. [23]. Exponentially growing tracheal submucosal cells, cultured on 
type IV collagen-coated T25flasks in RPMI 1640 medium (Intermed, 
France) supplemented with 2070 Ultroser G (a serum substitute from 
IBF, France), were harvested by treatment with 0.25°70 trypsin, 0.5 
mM EDTA in Ca z + -free phosphate buffered saline. The cell suspen- 
sions were rinsed 3 times with fresh culture medium and seeded on 
(24.5 mm diameter, 0.4 #m pore size) type I and III collagen-coated 
membranes (Transwell-COL membranem, Costar, Cambridge, MA) 
at a density of 0.5 x 10 6 cells per cm 2. Filter-grown tracheal gland 
cells were cultured in the presence of 2°70 Ultroser G added to the
apical (1.5 ml) and basal (2.5 ml) compartments of the culture 
chamber and maintained at 37°C under 5% COz in air. Ten days after 
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reaching confluency, filter-grown cells were rinsed 3 times with 
Ultroser G-free RPMI 1640 medium and cultured for 3 days in 
Ultroser G-free medium containing insulin (1 /zg/ml), transferrin (1 
#g/ml), epidermal growth factor (10 ng/ml), hydrocortisone (0.5 
~g/ml) and retinoic acid (10 ng/ml). The hormone-supplemented 
medium was placed in each compartment and changed daily. All 
culture media contained 2 mM L-glutamine, streptomycin (100 
ttg/ml) and penicillin (100 U/ml). We confirmed that confluent cells 
grown in Transwell-COL membranes exhibited characteristics of
epithelial and secretory cell, including dome formation and positive 
immunocytochemical st ining for cytokeratin. Lysozyme, a secretory 
protein marker specific to the human tracheal serous gland cell [24], 
was detected in the culture media (data not shown). 
2.2. Tightness of filter-grown cell monolayers 
To demonstrate he polarized secretion of proteins in apical and 
basal compartments, we verified that the confluents cells grown in 
Transwell-COL filters remained impermeable to secretory proteins 
during the course of the experiments. The tightness of confluent ceils 
was assessed by means of the technique described by Chambard et al. 
[25]. Ultroser G-free RPMI 1640 medium was added to the apical side 
while 2070 Ultroser G-supplemented medium was added to the basal 
side. The culture chambers showing < 1 070 of the basal concentration 
in the apical side after 24 h at 37°C were selected for this study. 
2.3. Metabolic labeling 
Culture chambers with confluent cells grown in the Transwell-COL 
membrane were maintained in the hormone-supplemented m ium 
(for 3 days) and rinsed 3 times with methionine-free RPMI 1640 
medium. After 1 h, the medium was then replaced with methionine- 
free RPMI 1640 medium containing 30 t~Ci/ml [35S]methionine (1000 
Ci/mmol, Amersham International) added to the basal compartment 
for 16 h, washed once quickly with fresh RPMI 1640 medium contain- 
ing an excess of unlabeled methionine and then, chased for 5 h at 
37°C in fresh RPMI 1640 medium in both compartments. Newly syn- 
thesized proteins, secreted in apical and basal medium, were collected 
separately, proteinase inhibitors (0.25 mM PMSF, 1000 U/ml 
aprotinin) were added and cell debris was removed by centrifugation. 
The Ca 2+ and phospholipid-binding proteins were selectively ex- 
tracted with EGTA from cell membranes, as previously described 
[26]. All samples were dialyzed exhaustively (Spectrapor tubing, MW 
cut off 6000 to 8000, Spectrum Medical Industries, L.A.) against 
deionized water for 8 days (2 changes a day), lyophilized and then 
stored at -80°C until used for biochemical nalysis. Total protein 
content was measured by the BioRad Protein Microassay Procedure 
[27]. Radioactivity was evaluated by mixing samples with Hionic- 
Fluor (Packard) and counting by liquid scintillation spectrometry. 
2.4. Immunofluorescence 
Procedures for indirect immunofluorescence of cultured human 
tracheal submucosal g and cells were as previously described [28]. We 
applied the biotin-streptavidin fluorescein technique using rabbit 
polyclonal antiserum to lipocortin I (dilution 1/25), fluorescein strep- 
tavidin and biotinylated goat anti-rabbit IgG (dilution 1/25, Amer- 
sham). Immunostaining was performed on fixed (3% parafor- 
maldehyde) and either non-permeabilized or permeabilized (0.1°70 
Triton X-100) cells grown on type I collagen-coated glass coverslips. 
2.5. Electrophoresis and immunoblotting 
SDS-polyacrylamide g l electrophoresis was performed in 10-15070 
gradient Phast gels according to the manufacturer's instructions 
(Pharmacia, France). After electrophoress, the dried gels were expos- 
ed to X Omat AR films (Kodak, France). For immunoblotting, pro- 
teins were transferred to nitrocellulose and probed with rabbit an- 
tiserum to lipocortin I (dilution 1/1000). Immunoreactive bands were 
visualized as described [29] using the biotinylated anti-rabbit IgG and 
streptavidin-biotinylated horseradish peroxidase complexes (dilution 
1/1000, Amersham). 
3. RESULTS AND DISCUSSION 
The  abi l i ty  o f  human t rachea l  g land  cells to  produce  
l ipocor t in - l i ke  prote ins  was invest igated  by us ing  in- 
Fig. 1. Surface immunofluorescence localization of lipocortin Iqike proteins from cultured human tracheal submucosal g and cells. Cells were fixed 
and non-permeabilized (A) or permeabilized with 0.1 070 Triton X-100 (B). Control cells using normal rabbit serum gave no staining. 
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direct immunofluorescence, s lective extraction pro- 
cedure of Ca 2÷ and phospholipid-binding proteins 
from cell membranes, fluorography following 
[aSS]methionine metabolic labeling and immunoblot- 
ting. We first performed immunofluorescence studies 
on fixed, non-permeabilized and permeabilized cells 
(Fig. 1). On subconfluent cell cultures, asignificant sur- 
face staining was observed using the lipocortin I an- 
tibody (Fig. 1A). After permeabilization, the cell mem- 
brane was clearly stained (Fig. 1B). On the other hand, 
no detectable fluorescence was obtained intracellularly. 
This indicates that human submucosal secretory cells 
contain a significant amount of membrane-associated 
lipocortin I-like proteins. The Ca 2 + and phospholipid- 
binding proteins from cell membranes were then 
analyzed by fluorography and immunoblotting follow- 
ing SDS-PAGE of EGTA extracts obtained from sub- 
mucosal gland cells labeled with [SSS]methionine. Two 
major radiolabeled calcium-dependent phospholipid- 
binding proteins with apparent Mr values of 45 and 67 
kDa were detected, respectively (Fig. 2, lane 1). To 
demonstrate that these Ca 2 *-dependent proteins 
belong to the lipocortin family, immunoblotting was 
performed using the lipocortin I antiserum. As shown 
in Fig. 2, lane 2, at least 4 polypeptides with apparent 
Mr values of 35, 40, 45 and 67 kDa were revealed, 
respectively, with the strongest immunoreactivity for 
the 35 kDa protein. We also investigated the vectorial 
delivery of exogenous secretory proteins to either the 
apical or basal cell surface of human tracheal gland cells 
1 
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Fig. 2. Identification f Ca 2 * and phospholipid-binding proteins 
present inEGTA extracts from cultured human tracheal submucosal 
gland cells. SDS-PAGE of proteins from cell membranes after 
fluorography (l) and immunoblotting using antiserum to lipocortin I 
(2). 
cultured on a permeable substrate. The newly synthesiz- 
ed proteins released by filter-grown cell monolayers 
during a 5 hour-chase period were analyzed by 
fluorography and immunoblotting following SDS- 
PAGE. More than 90% of radiolabeled proteins (93°7o, 
mean of 8 filters, range 4.5%) released by filter-grown 
cell were present in the apical medium. The amount of 
secretory proteins released during the 5 hour-chase 
period was approximately 45 /~g and 5 #g/culture 
chamber in the apical and basal medium, respectively. 
Fluorography ofproteins released in the apical medium 
(Fig. 3, panel I, lane A) revealed, at least, 15 radiolabel- 
ed polypeptides with Mr values ranging from 14 to 95 
kDa. Two major polypeptides of apparent Mr values of 
14.4 and 40 kDa were detected, respectively. Based on 
the molecular mass and immunoblotting characteristics 
followed by immunoenzymatic assays of the apical 
medium, the labeled Mr 14.4 kDa protein band has been 
identified as lysozyme, a secretory protein marker 
specific to the human tracheal serous gland cell [24] (F. 
Dupuit et al., in preparation). As yet, the identity of the 
labeled Mr 40 kDa band is unknown. Using im- 
munoblotting, antilipocortin I antiserum revealed a 
group of 3 polypeptides with apparent Mr values of 33, 
35 and 37 kDa, respectively, and a 68 kDa protein, 
secreted in the apical medium (Fig. 3, panel II, lane A). 













Fig. 3. Polarized secretion of newly synthesized proteins from human 
tracheal gland cells. The apical (A) and basal (B) culture medium 
from the 5 hour-chase period were analyzed by SDS-PAGE and 
fluorography (panel I) or by immunoblotting using antiserum to 
lipocortin I (panel If). Control immunoblotting using normal rabbit 
serum gave no immunoreactive staining. The positions of molecular 
mass markers (phosphorylase b, bovine serumalbumin, ovalbumin, 
carbonic anhydrase, soybean trypsin inhibitor and a-lactalbumin) are 
indicated. 
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This finding suggests that lipocortin I, recently 
demonstrated in human lung lavage fluid and defined 
as two lipocortin forms probably produced by alveolar 
macrophages with apparent Mr values of 34 and 37 
kDa, respectively [30], originates at least in part, from 
tracheal submucosal gland cells. The lipocortin I (35 
kDa) and other lipocortin-related proteins (15, 30, 32, 
36, 45 and 67-70 kDa) have been also identified in 
various cells and tissues such as bovine lung [31], 
cultured rat renomedullary interstitial cells [4], porcine 
thyroid cells [32], human endothelial cells [33] and 
human mononuclear cells [34]. Several reports have 
shown that the 35 kDa and 67-70 kDa lipocortin-like 
protein are closely related with respect to sequence, an- 
tiserum cross-reactivity and binding of Ca 2+ and 
phospholipid (see [35] for refs). Lipocortin I is a 
substrate for both the EGF receptor tyrosyl kinase [36] 
and the protein kinase C (PKC) [2,37]. Antonicelli et al. 
[32] recently showed that among four proteins (32, 35, 
36 and 67-70 kDa) of the lipocortin family, only 
lipocortin I was the endogenous substrate for the PKC 
in thyroid-stimulating hormone (TSH) treated cells. 
This is the first evidence that lipocortin-like proteins 
can be produced and released by human airway sub- 
mucosal secretory cells. This finding is consistent with 
a previous tudy [19] demonstrating that lipocortin is a 
possible mediator of the suppressive ffect of dex- 
amethasone on respiratory glycoconjugate s cretion. 
Airway gland cells are known to be targets for glucocor- 
ticosteroids [20]. The 35 kDa lipocortin identified in 
EGTA extracts from cultured tracheal submucosal 
gland cells could be a candidate for the glucocor- 
ticosteroid action. The 35 and 36 kDa lipocortins also 
bind phospholipid and actin in a Ca 2 + -dependent man- 
ner, and may have a role in crosslinking the plasma 
membrane and cytoskeleton during thesecretory vesicle 
release [38]. The extracellular presence of lipocortins 
has been also reported from cultured cell lines, and 
acted exogenously by inhibiting the formation of 
arachidonic acid metabolites [4,34,39,40]. In airways, it 
is now becoming clear that human tracheal epithelial 
cells can produce several cyclooxygenase products uch 
as 15-HETE and prostaglandin E2 [12-15], and may be 
partly responsible for the inflammatory diseases of the 
lung such as asthma. The anti-inflammatory actions of 
glucocorticoids include the inhibition of the release of 
arachidonic acid derivatives and the increase of lipocor- 
tin levels [40] associated with a significant reduction in 
respiratory glycoconjugate s cretion [19]. Lipocortins 
are presumed to be responsible for the anti- 
inflammatory effect of the corticosteroids (see [41] for 
refs). However, recent data have shown, in human 
cultured endothelial cells [33], that an increased syn- 
thesis of lipocortin cannot account for the inhibition of 
prostaglandin synthesis brought about by dex- 
amethasone. In L969 fibrosarcoma ceils [42], the pro- 
tective effect of dexamethasone appears not to be 
mediated by lipocortins. It has been proposed that 
lipocortins are involved in phospholipid-cytoskeleton 
interaction, exocytosis and membrane traffic 
[21,22,38]. 
These data emphasize the importance of human 
tracheal submucosal gland cell cultures for studies of 
the regulatory effects of glucocorticoids on respiratory 
glycoconjugate s cretion. Further experiments are re- 
quired to elucidate the exact role of these lipocortins 
produced by human tracheal submucosal g and cells. 
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